Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma

被引：3

作者：

Zhang, Wenqi ^{[1
]}

Huang, Chen ^{[1
,2
]}

Liu, Ruixia ^{[1
]}

Zhang, Huichao ^{[3
]}

Li, Weijing ^{[1
]}

Yin, Shaoning ^{[1
]}

Wang, Lianjing ^{[1
]}

Liu, Wei ^{[1
]}

Liu, Lihong ^{[1
,2
]}

机构：

[1] Hebei Med Univ, Hosp 4, Dept Hematol, Shijiazhuang, Peoples R China

[2] Hebei Prov Key Lab Tumor Microenvironm & Drug Resi, Shijiazhuang, Peoples R China

[3] Hebei Med Univ, Hosp 4, Clin Lab, Shijiazhuang, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷

关键词：

scnsl; CD19 CAR-T cell therapy; BTK inhibitor; PD-1; antibody; zanubrutinib; tislelizumab; EFFICACY;

D O I：

10.3389/fimmu.2022.983934

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Current therapeutic strategies for central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) are extremely limited. Secondary central nervous system lymphoma (SCNSL) also shows a grave prognosis and high mortality. This report describes a young female patient with DLBCL and CNS relapse who received low-dose CD19-directed chimeric antigen receptor T (CAR-T) cell therapy followed with Bruton's tyrosine kinase inhibitor and programmed cell death protein 1 antibody after several lines of chemotherapy. However, limited reports on CAR-T cell therapy are applied for SCNSL, particularly those in combination with targeted agents. The current treatment combination for this case provides a new regimen for CNS relapse from DLBCL.

引用

页数：8

共 33 条

[1] Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma
Abramson, Jeremy S.
McGree, Brianne
Noyes, Sarah
Plummer, Sean
Wong, Curtis
Chen, Yi-Bin
Palmer, Edwin
Albertson, Tina
Ferry, Judith A.
Arrillaga-Romany, Isabel C.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (08) : 783 - 784
[2] CAR T-cell therapy for secondary CNS DLBCL
Ahmed, Gulrayz
Hamadani, Mehdi
Shah, Nirav N.
[J]. BLOOD ADVANCES, 2021, 5 (24) : 5626 - 5630
[3] CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
Ayed, Ayed O.
Chiappella, Annalisa
Pederson, Levi
Laplant, Betsy R.
Congiu, Angela Giovanna
Gaidano, Gianluca
Spina, Michele
Re, Alessandro
Cavallo, Federica
Musuraca, Gerardo
Macon, William R.
Witzig, Thomas
Vitolo, Umberto
Nowakowski, Grzegorz S.
[J]. BLOOD CANCER JOURNAL, 2018, 8
[4] Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Bernard, Elsa
Nannya, Yasuhito
Hasserjian, Robert P.
Devlin, Sean M.
Tuechler, Heinz
Medina-Martinez, Juan S.
Yoshizato, Tetsuichi
Shiozawa, Yusuke
Saiki, Ryunosuke
Malcovati, Luca
Levine, Max F.
Arango, Juan E.
Zhou, Yangyu
Sole, Francesc
Cargo, Catherine A.
Haase, Detlef
Creignou, Maria
Germing, Ulrich
Zhang, Yanming
Gundem, Gunes
Sarian, Araxe
van de Loosdrecht, Arjan A.
Jadersten, Martin
Tobiasson, Magnus
Kosmider, Olivier
Follo, Matilde Y.
Thol, Felicitas
Pinheiro, Ronald F.
Santini, Valeria
Kotsianidis, Ioannis
Boultwood, Jacqueline
Santos, Fabio P. S.
Schanz, Julie
Kasahara, Senji
Ishikawa, Takayuki
Tsurumi, Hisashi
Takaori-Kondo, Akifumi
Kiguchi, Toru
Polprasert, Chantana
Bennett, John M.
Klimek, Virginia M.
Savona, Michael R.
Belickova, Monika
Ganster, Christina
Palomo, Laura
Sanz, Guillermo
Ades, Lionel
Della Porta, Matteo Giovanni
Smith, Alexandra G.
Werner, Yesenia
[J]. NATURE MEDICINE, 2020, 26 (10) : 1549 - +
[5] A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma
Chen, Xinfeng
Li, Xin
Liu, Yanfen
Zhang, Zhen
Zhang, Xudong
Huang, Jianmin
Li, Hong
Li, Feng
Zhang, Lei
Li, Ling
Wu, Xiaolong
Ma, Wang
Sun, Zhenchang
Yu, Hui
Zhou, Zhiyuan
Feng, Xiaoyan
Cui, Kang
Li, Zhaoming
Zhang, Hongling
Zeng, Ying
Wan, Xiaochun
Chen, Youhai H.
Zhang, Mingzhi
Zhang, Yi
[J]. IMMUNOTHERAPY, 2020, 12 (10) : 681 - 696
[6] Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib
Cheng, Qiansong
Wang, Jing
Lv, Chenglan
Xu, Jingyan
[J]. ONCOTARGETS AND THERAPY, 2021, 14 : 3367 - 3372
[7] Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, Leonid
Morello, Aurore
Villena-Vargas, Jonathan
Feng, Yang
Dimitrov, Dimiter S.
Jones, David R.
Sadelain, Michel
Adusumilli, Prasad S.
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (08) : 3130 - 3144
[8] Revised response criteria for malignant lymphoma
Cheson, Bruce D.
Pfistner, Beate
Juweid, Malik E.
Gascoyne, Randy D.
Specht, Lena
Horning, Sandra J.
Coiffier, Bertrand
Fisher, Richard I.
Hagenbeek, Anton
Zucca, Emanuele
Rosen, Steven T.
Stroobants, Sigrid
Lister, T. Andrew
Hoppe, Richard T.
Dreyling, Martin
Tobinai, Kensei
Vose, Julie M.
Connors, Joseph M.
Federico, Massimo
Diehl, Volker
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 579 - 586
[9] Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
Chong, Elise A.
Ruella, Marco
Schuster, Stephen J.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07) : 673 - 674
[10] Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma
El-Galaly, Tarec Christoffer
Cheah, Chan Yoon
Bendtsen, Mette Dahl
Nowakowski, Grzegorz S.
Kansara, Roopesh
Savage, Kerry J.
Connors, Joseph M.
Sehn, Laurie H.
Goldschmidt, Neta
Shaulov, Adir
Farooq, Umar
Link, Brian K.
Ferreri, Andres J. M.
Calimeri, Teresa
Cecchetti, Caterina
Dann, Eldad J.
Thompson, Carrie A.
Inbar, Tsofia
Maurer, Matthew J.
Gade, Inger Lise
Juul, Maja Bech
Hansen, Jakob W.
Holmberg, Staffan
Larsen, Thomas S.
Cordua, Sabrina
Mikhaeel, N. George
Hutchings, Martin
Seymour, John F.
Clausen, Michael Roost
Smith, Daniel
Opat, Stephen
Gilbertson, Michael
Thanarajasingam, Gita
Villa, Diego
[J]. EUROPEAN JOURNAL OF CANCER, 2018, 93 : 57 - 68

← 1 2 3 4 →